. Finally, we report a functional synergism between TAF II s and the TRAP/Mediator complex in activated transcription, manifested as hTAF II -mediated inhibition of basal transcription and a consequent TRAP requirement for both a high absolute level of activated transcription and a high and more physiological activated/ basal transcription ratio. These results suggest a dynamic TFIID structure in which the switch from a basal hTAF II -enhanced repression state to an activator-mediated activated state on a promoter may be mediated in part through activator or coactivator interactions with hTAF II 135.
TFIID is a general transcription factor composed of a small TATA-binding polypeptide and a large number of TATAbinding protein (TBP)-associated factors (TAFs), all of which are highly conserved in evolution (reviewed in references 7 and 17) . TFIID is involved, along with other general initiation factors (TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH), in both activator-independent (basal) and activator-dependent transcription. Furthermore, and in contrast to basal transcription, activator-dependent transcription in mammalian cell-free systems reconstituted with purified factors generally requires cofactor activities that include both USA (upstream factor stimulatory activity)-derived factors and TBP-associated factors (TAF II s) within TFIID (for reviews, see references 28, 35, 37, and 38) .
In general, the efficiency of preinitiation complex (PIC) assembly or function is controlled by the presence of transcription factors that are usually bound to specific distal sequences. Some models of how transcription regulatory factors influence PIC assembly invoke interactions with TFIID that, through qualitative and/or quantitative effects on TFIID binding, enhance the recruitment of downstream factors (reviewed in reference 7). Whereas TFIID from metazoans was found to mediate both basal and activator-dependent transcription in cell-free systems reconstituted with partially purified components, TBP elicited mainly basal transcription. This led to the hypothesis that TAF II s within TFIID interact directly with activators to promote PIC assembly. Conversely, and using reconstituted TFIID complexes, a seemingly good correlation was drawn between the activity of a specific activator and the ability of its activation domain to selectively bind a specific given TAF II (for reviews, see references 7 and 43). In addition, in vitro studies have shown an important role for TAF II s within TFIID in core promoter recognition and transcriptional strength, especially on TATA-less promoters that contain other core promoter elements such as the initiator (Inr) and/or downstream promoter elements (for a review, see reference 40) . In this regard, early in vivo studies in Saccharomyces cerevisiae suggested that individual TAF II s are dispensable for activated transcription of most genes (31, 44) and that core promoter elements, rather than upstream binding sites, confer TAF II -dependence on some genes (39) .
Consistent with these latter observations is the finding that the S. cerevisiae Mediator complex can support activated transcription in vitro with TBP alone (22, 25) . In addition, it was also reported that TAF II s are not required either for activated transcription by GAL4-VP16 in unfractionated HeLa nuclear extracts (34) or for activation by thyroid hormone receptor in association with the human TRAP/Mediator in a partially purified system (15) . However, in a reexamination of the TAF II requirement for activator function in S. cerevisiae, more extensive genetic analyses have suggested that at least some TAF II s (notably the histone-related TAF II s) are broadly required for transcription and that the TAF II dependency, in some cases, may require upstream activators (reviewed in ref- erence 17) . Finally, and further complicating the interpretation of the in vivo assays, is the discovery that a subset of TAF II s found in the TFIID complex are also integral components of histone acetyltransferase complexes in S. cerevisiae and humans (for review, see reference 6). Thus, TAF II s have been shown to serve as conventional coactivators acting at the DNA level, as core promoter-selective factors, and within coactivators implicated in chromatin modifications, and at least one TAF II has several catalytic activities that are potentially involved in transcription (reviewed in reference 17). It thus seems likely that different TAF II s may function by distinct mechanisms that depend on the specific regulatory elements and chromosomal architecture of a given promoter.
An understanding of the various TFIID functions is based on a resolution of the overall architecture of TFIID that requires knowledge of both the primary sequences and structures of individual subunits and their interactions and topological organization within TFIID (1, 5) . Studies of S. cerevisiae, Drosophila melanogaster, and human TAF II s have provided valuable information on a number of protein-protein interactions and, of special interest, the potential for a histone octamer-like structure within TFIID that would comprise, in the human system, the H4-like (hTAF II 80), the H3-like (hTAF II 31) , and the H2B-like (hTAF II 20) subunits (21) .
Here we describe interactions of the H2A-related hTAF II 135 with the H2B-related hTAF II 20 through histone-like folds (16, 21) and the importance of this interaction for human TFIID assembly. We also report important new insights into TFIID function based on the demonstration of synergistic hTAF II 135-TFIIA interactions that relieve hTAF II 250-mediated inhibition of TBP binding and function, as well as a functional synergism between TAF II s and the TRAP/Mediator complex.
MATERIALS AND METHODS
Isolation of cDNA clone for hTAF II 135. TFIID was affinity purified from either HeLa nuclear extract (NE) or a phosphocellulose (Whatman P11) fraction (0.85 KCl) of HeLa NE by use of an antibody against the N-terminal portion of hTAF II 100 or anti-TBP antibodies, respectively (42) . The 135-kDa polypeptide was excised and digested with endoproteinase Lys-C (13) . Earlier sequence analysis of the purified peptides yielded several sequences that were used to design degenerate oligonucleotides and to isolate the cDNA corresponding to the truncated hTAF II 135 sequence (amino acids 239 to 1083). Subsequent hTAF II 135 peptide sequence analysis revealed two additional peptides. The sequence of one of these two peptides matched the translation of a genomic DNA clone (accession number Z22478). The sequences of this genomic clone were used to obtain the missing 5Ј region of hTAF II 135 DNA coding region. The full-length coding DNA sequence (amino acids 1 to 1083) that was obtained is identical to the one reported by Mengus et al. (30) .
Expression and purification of TFIID subunits, activators, and GST derivatives. The pVL derivatives for the expression of hemagglutinin (HA)-hTAF II 250, Flag-hTAF II 100, Flag-hTAF II 80, Flag-hTAF II 55, Flag-hTBP, Flag-hTAF II 31 , and Flag-hTAF II 28 have been described (11, 18, 19, 42) . Expression pVL plasmids for Flag-hTAF II 150, Flag-hTAF II 135, Flag-hTAF II 20, and HA-hTAF II 20 were constructed by PCR. In each case, an NdeI site at the N-terminal end and an appropriate restriction enzyme site at the C-terminal end following the natural stop codon were created. The large number of primers used in the PCRs has precluded description of their exact sequences, but the information is available upon request. The PCR-generated fragments were then inserted into adapter pFlag(S)-7 and pFlag (AS)-7 plasmids carrying the appropriate tag epitope (10) and subsequently subcloned into either pVL-1392 or pVL-1393 (41) . Each construct was verified by sequencing.
For each TFIID subunit, an individual recombinant baculovirus was generated by cotransfecting corresponding cDNA and BacVector-3000-linearized baculovirus DNA (Novagen) into Sf9 cells. Each recombinant baculovirus was further amplified by repeated infection of Sf9 cells. For production of recombinant proteins, Sf9 cells were infected by the corresponding recombinant viruses and harvested 48 h postinfection. For the coinfection experiments, the appropriate ratio between the viruses was determined by pilot assays before the large coinfection experiments were performed. Recombinant proteins were purified from infected cells. Nuclear extracts were prepared in buffer C (20 mM Tris [pH 7.9], 20% glycerol, 0.2 mM EDTA) containing 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 10 g of leupeptin per ml, and 1 g of pepstatin per ml, 400 mM KCl (BC400), and 0.1% NP-40 (13) . Clarified extracts were subjected to the appropriate method of purification, affinity purification on anti-Flag antibody (M2 agarose; Kodak) or anti-HA antibody (12CA5 monoclonal antibody) columns, and further purified by one or two steps of ion-exchange chromatography. The recombinant proteins were more than 90% pure as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue or silver staining.
Glutathione S-transferase (GST) constructs were created by inserting cDNA fragments corresponding to the different proteins and flanked, in frame, with the appropriate restriction sites into pGEX vector. GST fusion proteins were expressed in Escherichia coli, solubilized by sonication of cells in lysis buffer (18) and removal of insoluble debris by centrifugation, and purified on glutathioneSepharose (Pharmacia); 1 g of purified protein was used for each binding assay.
Bacterially expressed Flag-Gal4 fusion protein p65 was purified as described previously (18) . Histidine-tagged full-length hTAF II 135 and hTAF II 135 deletion mutants were constructed and cloned in the 6HisT-pRSET vector.
Generation of antibodies against hTAF II 135. A cDNA corresponding to the C-terminal portion of hTAF II 135 was amplified by PCR with the appropriate restriction enzymes. The PCR-generated fragment was then inserted into bacterial expression construct pET11d (Novagen), which carries the six-histidine tag. The recombinant protein was then expressed in and purified from bacteria and subjected to preparative SDS-PAGE. Gel slices containing the corresponding protein were crushed and used for immunization of two rabbits.
Generation of hTAF II 135 cell line. A HeLa cell line constitutively expressing Flag-hTAF II 135 (f:135) was made using the pCIN4 expression vector (36) .
Far Western blotting. The baculovirus-expressed and purified hTAF II 135 was labeled with 32 P at the heart muscle kinase site present in the Flag-tagged sequence (10) by incubation with heart muscle kinase and [␥-32 P]ATP for 30 min at 30°C. Labeled protein was then purified through a nick column (Pharmacia) and used for protein-blot interactions as described (4) .
Gel filtration. Purified TFIID preparations from either f:135 or f:TBP cell lines were fractionated on Superose 6 (Smart System; Pharmacia) in buffer BC200 containing 0.05% NP-40. Fractionated proteins were resolved by SDS-PAGE and visualized by silver staining.
DNase I footprinting. Plasmid pML4, containing the major late promoter, was used for DNase I footprinting as described (10) . Briefly, the EcoRI-HindIII DNA fragment from pML4 was isolated and end labeled with 32 P by T4 polynucleotide kinase. Cleavage of the DNA fragment with XbaI generated a specific labeled transcribed strand. DNase footprinting reactions and the processing of the labeled products were performed essentially as described previously (10) .
In vitro RNA polymerase II transcription assays. Nuclear extracts were prepared as previously described (12) . TFIID, TFIIH, and the Flag-thyroid hormone receptor alpha (TR␣)-TRAP complex were purified from cell lines expressing Flag-TBP, Flag-hTAF II 135, Flag-ERCC3, and Flag-TR␣, respectively, using affinity purification on anti-Flag antibody columns as previously described (10, 15, 18) . Flag-TR␣ and Flag-retinoid X receptor alpha (RXR␣) were purified from Sf9 cells as previously described (14) . Native TFIIA was purified as previously described (18) . For TFIIA (p55 and p12), TFIIB, TFIIE␣, and TFIIE␤ recombinant Flag-tagged proteins were expressed in and purified from E. coli using an anti-Flag antibody column (M2 agarose; Kodak). Histidine-tagged TBP and TFIIF subunits (RAP30 and RAP74) were prepared as described previously (18) . TFIIA and TFIIF were then reconstituted from individually purified components following denaturation and renaturation (45) . RNA polymerase II was purified essentially as described previously (3) .
Using the purified transcription factors described above, in vitro transcription assays were carried out in 25-l reaction mixtures containing 20 ng of pML⌬53 or pML200 templates and 50 ng of either pG 5 E1b or pTRE 3 pML⌬53 templates. All transcription factors were added simultaneously to the reactions if not indicated otherwise in the figure legends.
32 P-labeled RNA was phenol-chloroform extracted, ethanol precipitated, analyzed directly by 4% polyacrylamide-urea gel electrophoresis, and visualized by autoradiography. Quantitation was done by phosphorimager.
Partial TFIID reconstitution. Following the method that we described earlier (18) , human hTAF II 250 or hTAF II 20 containing a fused N-terminal HA epitope tag was immobilized on protein A-Sepharose containing covalently linked monoclonal antibodies directed against the HA epitope. After extensive washing (BC1000 with 0.1% NP-40), the beads were incubated sequentially (at 4°C for 4 h) with molar excesses of additional TFIID subunits. After each incubation, unbound materials were removed by several washes with 100 volumes of BC150 (with 0.1% NP-40). Finally, the resulting complex was eluted with HA peptide (1 mg/ml) in BC100 (with 0.1% NP-40).
In vitro protein-protein interaction assays. Sp1 activation domains A and B, TFIIA subunits p12 and p55, hTAF II 20, and hTBP were expressed in and purified from bacteria as GST fusion proteins. Histidine-tagged full-length hTAF II 135 and hTAF II 135 deletion mutant constructs were expressed in the TNT reticulocyte lysate system (Promega) and labeled with [ 35 S]methionine according to the manufacturer's instructions. Equivalent inputs of radioactive material of full-length hTAF II 135 and hTAF II 135 deletion mutants were used for binding studies with different GST derivatives. In each reaction, 1 g of purified GST or GST derivative was immobilized on glutathione, and the appropriate input material was added to each reaction (in 300-l total volume in BC300 plus 0.1% NP-40). After incubation at 4°C for 2 h, the beads were washed four times with 300 l of incubation buffer, and bound proteins were eluted with SDS loading buffer and analyzed by SDS-PAGE and autoradiography. 20 was by far the strongest among all TFIID subunits, we speculated that it might have important consequences for de novo assembly of TFIID and, in particular, the recruitment of hTAF II 135. Furthermore, although one essential feature of the original octamer-like model was the presence of two hTAF II 20 molecules in TFIID, there was no apparent H2A-like partner for hTAF II 20 (which was assumed to heterodimerize).
RESULTS

Strong and specific interaction of hTAF
To test the suggestion (above) of an hTAF II 20-interacting domain within hTAF II 135 as a potential candidate for an H2A-like partner for hTAF II 20 , radiolabeled hTAF II 135 deletion mutants were analyzed for their ability to interact with hTAF II 20 (immobilized as a GST-hTAF II 20 fusion protein). hTAF II 20 interacted with the hTAF II 135 C-terminal fragment (486 to 1083), but not with the N-terminal fragment (1 to 575) ( Fig. 2A ). Further mapping revealed that an hTAF II 135 fragment comprised of residues 486 to 896 interacts weakly with hTAF II 20, whereas a fragment comprised of residues 897 to 1083 interacts strongly with hTAF II 20 ( Fig. 2B ). This shows that hTAF II 20 interaction domain in hTAF II 135 is located in the extreme C-terminal region. While this work was in progress, Gangloff et al. (16) showed that hTAF II 20 can interact with the C-terminal portion (residues 870 to 951) of hTAF II 135 in a yeast two-hybrid assay. Based on their mapping data between hTAF II 15) revealed the presence of these components both in TFIID purified from the f:135 cell line and in TFIID prepared from the f:TBP cell line (Fig. 3B ). Significantly, however, there was a clear enrichment of hTAF II 20 (and the hTAF II 15 isoform) in the TFIID preparation from the f:135 cell line compared to that from the f:TBP cell line when normalized to the content of TBP and other TAFs (Fig. 3B) . These data are consistent with the observed in vitro interaction between hTAF II 20 and hTAF II 135. The data further show copurification of natural endogenous hTAF II 135 and exogenous Flag-hTAF II 135 (Fig. 3A) in the TFIID that was affinity purified (via f:135) on anti-Flag antibody columns and in the same ratio that they are expressed in the f:135 cell line (Fig. 3C) . Furthermore, a Western blot with anti-Flag antibody revealed only one band, corresponding to the exogenous Flag-tagged TAF II 135, in the TFIID purified from the f:135 cell line and no reactive bands in TFIID purified from the f:TBP cell line (data not shown). Since there is no apparent self-association of hTAF II 135 (Fig. 1) , this clearly indicates the presence of at least two molecules of hTAF II 135 within the TFIID complex.
The enrichment of hTAF II 20 in the TFIID preparation from the f:135 cell line could be due to an increased hTAF II 135 occupancy in the TFIID and/or to the simple association of hTAF II 20 with a fraction of overexpressed Flag-hTAF II 135 protein that is purified with, but not incorporated into, TFIID. To test this, we further fractionated purified TFIID complexes from f:135 and f:TBP cell lines on Superose 6 (Smart System). Silver staining of the Superose 6 fractions from the f:135 cellderived TFIID revealed two hTAF II 135-containing peaks (Fig.  3D) . The first peak eluted at a position corresponding to a size greater than 1 MDa (Fig. 3D, fraction 10 ) and coincided exactly with the single peak obtained upon fractionation of TFIID purified from the f:TBP cell line (Fig. 3E, fraction 10) . It also contained TBP and a normal complement of TAFs and thus corresponds to TFIID. Significantly, however, the TFIID preparation from the f:135 cell line showed an increased occupancy of both hTAF II 135 and hTAF II (Fig. 4, lanes 2 and 3) , the subsequent addition of other TAF II s (hTAF II 150, hTAF II 100, and hTAF II 80) resulted in the dissociation of previously bound hTAF II 135 (data not shown). In addition, hTAF II 135 failed to stably associate with a preformed complex comprised of immobilized hTAF II 250, TBP, hTAF II 80, and hTAF II 31 (Fig. 4, lane 4) , indicating that such an association requires an additional TAF(s). In this regard, addition to the TFIID assembly mixture of hTAF II 20, along with the histone H3-and H4-like TAF II s (hTAF II 31 and hTAF II 80), greatly facilitated the incorporation of hTAF II 135 (Fig. 4, lane 6 versus lane 5) and, subsequently, hTAF II 100 (Fig. 4, lane 7) . It is also possible that hTAF II 135 gets incorporated into de novoassembled TFIID as a complex with hTAF II 20. These results show a requirement for hTAF II 20 , along with other histone fold-containing TAFs (hTAF II 31 and hTAF II 80), for the stable incorporation of hTAF II 135 into assembling TFIID, which is consistent with the in vivo data obtained with the f:135 cell line (Fig. 3) . Our data clearly demonstrate a new pathway for the assembly of human TFIID that stresses the importance of hTAF II 135-hTAF II 20 interactions and is thus distinct from the pathway proposed for Drosophila TFIID. In the latter case, earlier assembly studies reported a simple association of dTAF II 110 (Drosophila homologue of hTAF II 135) with a TBP-dTAF II 250 complex, followed by sequential association of dTAF II 150 and the smaller Drosophila TAFs (9) .
TAF II 135 interacts with TFIIA subunits. In light of previously described interactions of the Drosophila homologue of hTAF II 135, dTAF II 110, with general factor TFIIA and with activation domains of Sp1 (20, 46), we examined protein-protein interactions of hTAF II 135 with individual TFIIA subunits and with Sp1 activation domains A and B. The individual p35, p19, and p12 subunits of TFIIA, the p55 precursor of p35 and p19, and Sp1 domains A and B were expressed as GST fusion proteins and used for solution interaction studies with [
35 S]methionine-radiolabeled full-length hTAF II 135. The results show that hTAF II 135 interacts with both the unprocessed TFIIA p55 and the derived p35 subunit, but not with the derived p19 subunit, and with the p12 subunit (Fig. 5A ). Further studies with several deletion mutants of hTAF II 135 (Fig. 5B ) revealed interactions of both TFIIA p55 (Fig. 5C ) and TFIIA p12 (Fig. 5D) with the extreme C-terminal region (897 to 1083) of hTAF II 135. alone showed no binding (Fig. 6B, lane 5 ), led to a strong binding of TBP to the TATA region (Fig. 6B , lane 6 versus lane 5). This clearly shows a synergy between TFIIA and hTAF II 135 that specifically relieves the inhibitory function of hTAF II 250 on TBP binding. These results are relevant to the natural TFIID, since the binding of natural TFIID on the adenovirus major late promoter is potentiated by TFIIA (data not shown). Furthermore, we have shown that a complex composed of TAF II 250, TAF II 80, and TBP failed to cooperate with TFIIA to relieve TAF II 250-mediated inhibition of TBP binding, thus demonstrating that the action of TAF II 135 and TFIIA is specific (data not shown).
Effects of TFIIA on basal and activated transcription in the presence of TFIID and partial TFIID complexes. To study the effects of TAF II s on basal and activated transcription, we compared the effects of equimolar amounts (based on TBP content) of f-TFIID and partial TFIID complexes. Partial in vitro-assembled TFIID species that contained hTAF II 135 in addition to TBP-TAF II 250 were designed to test the potential core promoter and coactivator functions of hTAF II 135. The transcription system consisted of recombinant and highly purified transcription factors from HeLa cells. The ability of this system to support both basal and activator-dependent transcription was tested simultaneously by using two templates whose correctly initiated G-less transcripts could be differentiated by their size. The activator-responsive template contained three thyroid hormone-responsive elements (TRE) upstream of the adenovirus major late promoter TATA box and natural initiator regions, and activation was mediated by TR, isolated in association with TRAP complex (14) , and RXR. . This could be due, at least in part, to the above-described (Fig. 6 ) ameliorative effect of TAF II 135 on the TAF II 250-mediated repression of TBP binding to DNA, especially since these effects are more apparent in the presence of TFIIA (below). Second, basal transcription in the presence of the complete TFIID was totally repressed as a result of the strong repressive effect of the TAFs as a group on TBP function (Fig. 7A, lane 5 versus lanes 1 and 3) . Thus, the complete complement of TAFs in TFIID appear to conditionally constrain the ability of TAF II 135 to reverse the TAF II 250-mediated repression of TBP function in basal transcription, but it is possible that this potential is reactivated in the presence of transcriptional activators. Third, and significantly, the absolute levels of TR-TRAP-activated transcription were slightly higher with TFIID than with the two partial complexes (Fig. 7A , lane 6 versus lanes 4 and 2). In addition, the fold activation (activated/basal transcription ratio) was much higher with TFIID than with the partial TFIID complexes, due mainly to the potent inhibitory effect of the TAFs as a group, in the complete TFIID, on TBP function in basal transcription (for quantitation, see legend to Fig. 7) . Because of the observed stimulatory effect of TFIIA on binding of the partial TFIID complexes to the major later promoter, we next asked whether TFIIA could affect basal and/or activated transcription by the intact and partial TFIID complexes tested above. Whereas addition of TFIIA with TBPhTAF II 250 and TBP-hTAF II 250-hTAF II 135 increased basal activity for these complexes (Fig. 7A, lanes 7 and 9 versus  lanes 1 and 3, respectively) , addition with TFIID had no discernible effect on the very low basal activity observed in its absence (Fig. 7A, lane 11 versus lane 5) . Furthermore, TFIIA slightly potentiated the activated transcription observed with intact TFIID but had no apparent effect on the absolute levels of activated transcription observed with partial TFIID complexes (Fig. 7A, lanes 8, 10, and 12 versus 2, 4 , and 6, respectively). These findings indicate a direct correlation between the effects of TFIIA on both the binding (Fig. 6 ) and the basal transcription of partial TFIID complexes (Fig. 7) . Moreover, like the functional assays in the absence of TFIIA (above), they also point to roles both for hTAF II 135 and for other TAFs in modulating core promoter function. Thus, it is again apparent that the positive effect of hTAF II 135 observed in the partial complex is constrained by the full complement of TAFs within TFIID and possibly utilized in this context only in activated transcription. Although these studies with TAF II 135 were performed in the absence of its histone fold partner, TAF II 20, similar results were observed when a TBP-TAF II 250-TAF II 135-TAF II 20 complex was analyzed (data not shown). Thus, our analysis has allowed us to assign TAF II 20-independent functions to TAF II 135.
Since the experiments described above were performed with either natural TFIID or partial TFIID complexes, we next asked whether TBP alone could mediate activated transcription in the presence of the TR-TRAP complex in this highly purified transcription system. To this end we compared the ability of TBP and TFIID (at approximately equimolar TBP concentrations based on quantitative Western blot analysis) to mediate TR-TRAP complex-activated transcription. The TR-TRAP complex (in conjunction with RXR) activated transcription more than 30-fold in the presence of natural TFIID and 13-fold in the presence of TBP alone (Fig. 7B, lane 2 versus  lane 1 and lane 4 versus lane 3, respectively) . These findings, along with our previously published data (15) , indicate that TAFs are not unconditionally required for a significant level of activated transcription at the level of free DNA template and that TRAPs might fulfill functional roles analogous or redundant to those performed by the TAFs in natural TFIID. Finally, and consistent with its effect on TBP binding (Fig. 6) , TFIIA increased the basal activity obtained with TBP alone (Fig. 7B, lane 7 versus lane 3) , but was without effect on the low basal activity with TFIID (Fig. 7B, lane 5 versus lane 1) or the absolute levels of TR-TRAP-mediated activity of either TBP (Fig. 7B, lane 8 versus lane 4) or TFIID (Fig. 7B, lane 6 versus  lane 2) . This results in a much higher fold stimulation by TR-TRAPs with TFIID than with TBP and is of significance because TFIID is the natural form of the TATA-binding factor and since basal (activator-independent) transcription activities are not observed physiologically.
Functional synergism between the TRAP complex and TAF II s. Since the above experiments concerned activated transcription in the presence of the activator TR and the interacting TRAP complex, we next asked whether the TRAP complex, which has been shown to mediate the function of many activators in concert with other positive cofactors such as PC4 (reviewed in reference 28), would exhibit synergistic or redundant functions with the TAFs in the presence of a different activator, fGAL4p65. fGAL4p65 consists of the DNA-binding domain (amino acids 1 to 94) of S. cerevisiae GAL4 fused to the potent C-terminal acidic activation domain of the NF-B p65 subunit. First, to study the effects of TAF II s on basal and activated transcription, we compared the effects of equimolar amounts (based on TBP content) of TBP and f-TFIID on both basal and fGAL4p65-activated transcription in the assay system described above. The test template contained five GAL4 binding sites upstream of the adenovirus E1b TATA and natural Inr regions. Basal transcription was assayed on a template containing only the adenovirus major late core promoter sequence and in a system reconstituted with general transcription factors and the general coactivator. In this assay, and in the absence of TRAPs, fGAL4-p65 strongly activated transcription in the presence of either natural TFIID or TBP (Fig. 8, lane 2 versus lane 1 and lane 6 versus lane 5, respectively; for quantitation, see figure legend). While absolute levels of activated transcription on the E1b promoter were threefold higher with TBP than with TFIID (Fig. 8, lane 6 versus lane 2) , basal activity was significantly less with TFIID than with TBP alone (Fig. 8, lane 5 versus lane 1; see figure legend) . This leads to a fold activation (activation/basal transcription ratio) that is actually higher for TFIID than for TBP alone. It is important to note that this high level of induction in the presence of TFIID is due to the potent inhibitory effect of TAFs as a group, within the complete TFIID, on TBP basal activity and the partial reversal of these effects by the activator (18) .
In this assay system, addition of the TRAP complex had no apparent effect on basal activity with either TFIID or TBP (Fig. 8, lane 3 versus lane 1 and lane 7 versus lane 5, respectively). Most significantly, however, the TRAP complex strongly (circa fivefold) enhanced the absolute level of activated transcription (mediated by GAL4p65) with TFIID (Fig. 8, lane  4 versus lane 2) , while having no effect on the absolute level of activated transcription with TBP alone (Fig. 8, lane 8 versus  lane 6) . Moreover, in the presence of the TRAP complex, the absolute level of activated transcription was slightly higher with TFIID than with TBP (Fig. 7A, lane 4 versus lane 8) . Thus, these results establish, for the first time, a synergism between the TRAP complex and the TAF II s that are naturally present in TFIID and, at least in some cases, inhibitory to the function of TBP. It is important to note that while activation is readily observed in the absence of both TAFs and TRAPs, the TAFs lower basal transcription to a more physiological level and, in doing so also elicit a requirement for TRAPs both for a high absolute level of activated transcription and for a high induction ratio.
DISCUSSION
The TAF II subunits of TFIID have been implicated both as targets for gene-specific activators (reviewed in references 7 and 43) and as modulators (negative and positive) of TFIID binding to diverse core promoter elements (for a review, see reference 38). Although not generally essential for basal transcription directed by TATA elements in core promoters, TAFs are essential for the function of other core promoter elements (initiator and downstream promoter element) either alone or in conjunction with the TATA elements (reviewed in references 17 and 38). As part of our ongoing effort to understand the assembly, structure, and function of human TFIID, we have focused, subsequent to cognate cDNA cloning and expression, on structure-function studies of hTAF II 135. We report both extended and novel functions of hTAF II 135 that include a critical role, dependent upon histone fold interactions, in TFIID assembly; a synergistic interaction with TFIIA that relieves the well-documented hTAF II 250-mediated inhibition of TBP binding and function (8, 23, 27, 33) ; and contributions to a functional synergy between TAFs and the human TRAP/Mediator complex in transcriptional activation. These findings support an increasing appreciation of TAFs as multifunctional components and TFIID as a dynamic complex subject to a variety of internal and external controls. 7) . The lower band, below the arrow indicating pML⌬53, is a transcript generated from the activator-responsive template. and the H3-like hTAF II 31, in the formation of an octamer-like substructure, as previously proposed for the human TFIID (21) . Other human TAFs, such as TAF II 28 (H3-like) and TAF II 18 (H4-like), have also been shown to contain histone folds (2) and to interact strongly with one another (29) .
The presence within TFIID of multiple TAFs with histone folds points to the role of this fold in stable protein-protein interactions between TAFs. Furthermore, and more significantly, we have shown that the hTAF II 135-hTAF II 20 interaction is critical for human TFIID assembly, since this interaction helps stabilize the recruitment of hTAF II 135, along with the other histone-like TAF II s (hTAF II 80, hTAF II 31 and hTAF II 20) , to an hTAF II 250-TBP complex. This core complex is competent to recruit other TAFs, such as hTAF II 100, which may play a role in the stabilization of histone-like TAF complexes (42) , and hTAF II 150. Our data on the assembly of the human TFIID indicate a novel pathway for the assembly of TFIID that is distinct from the one reported for the assembly of Drosophila TFIID (9) and point to important roles played by the histonelike motifs in this process. The conservation of this mechanism is suggested by the presence of hTAF II 20, hTAF II 31, PAF65␣ (homologue of hTAF II 80), PAF65␤ (homologue of hTAF II 100), and hTAF II 100 in human PCAF and GCN5 complexes and the presence of the S. cerevisiae homologues of hTAF II 20, hTAF II 31, hTAF II 80, and hTAF II 100 in the S. cerevisiae SAGA complex (6) .
hTAF II 135 interacts with TFIIA to specifically relieve hTAF II 250-mediated inhibition of TBP binding and function. We have shown that hTAF II 135 interacts with two (the largest and the smallest) of the three subunits of TFIIA. These data confirm and extend an earlier observation of an interaction of dTAF II 110, the Drosophila homologue of hTAF II 135, with the large subunit of Drosophila TFIIA (46) . A more detailed analysis with hTAF II 135 deletion mutants further shows that the human TFIIA subunit interactions are mediated through the C-terminal portion of hTAF II 135. Most importantly, from a functional standpoint, an analysis with highly purified TFIIA and in vitro-assembled TFIID subspecies has shown that the interaction of TFIIA with hTAF II 135 has a critical role in relieving hTAF II 250-mediated repression. Thus, these studies with partial TFIID species have revealed an internal mechanism involving hTAF II 135 that could be used in a structurally dynamic natural TFIID to facilitate the transition from TAF IImediated repression to activation. This leads to speculation that hTAF II 135 may be a direct or indirect (e.g., via TFIIA) target for factors that use it to relieve repression during activated transcription. Although TFIIA was shown to have a role in countering inhibitory interactions of the amino terminus of the S. cerevisiae TAF II 145 (the S. cerevisiae homologue of the human hTAF II 250) with TBP (24), our observations are the first to show a synergism between TFIIA and a specific TAF II subunit in relieving hTAF II 250-mediated repression. They further demonstrate new core promoter functions for both TFIIA and hTAF II 135.
TAF II 135 core promoter function. In the context of TFIID, TAF II s appear to have coactivator functions mainly on the basis of in vitro studies with metazoan factors (for reviews, see references 38 and 43), whereas core promoter-selective functions are evident from in vivo studies in S. cerevisiae (for a review, see reference 17) and from both in vivo and in vitro studies in metazoans (for review, see reference 38). The transcriptional requirement of TAF II s was assessed originally in purified (reconstituted) cell-free systems in which TBP alone efficiently supported basal but not activator-mediated transcription for several activators. Since TFIID supported both basal and activated transcription in vitro, one or more TAF II s appeared to have a critical coactivator function under the conditions employed. These results, the demonstrations of in vitro interactions between activation domains and isolated TAF II s, and studies with partial (reconstituted) TFIID complexes led to the proposal, consistent with earlier demonstrations of qualitative and quantitative effects of activators on TFIID binding, that TAF II s are direct targets for activators (reviewed in references 7 and 43). The prototype for this paradigm was the activator Sp1 with its proposed "obligate" direct target, dTAF II 110, the Drosophila homologue of hTAF II 135 (9, 20) .
Here we have shown that the partial TFIID complexes TBPhTAF II 250 and TBP-hTAF II 250-hTAF II 135, like TBP alone (15) , can mediate robust activated transcription by the TR-TRAP complex. However, the TBP-TAF II 250-hTAF II 135 complex mediates higher basal transcription than the TBP-TAF II 250 complex, and this effect of hTAF II 135 can be potentiated by TFIIA on the adenovirus major late promoter. Interestingly, similar data for basal transcription were also obtained with partial TFIID complexes using a different core promoter with Sp1-responsive elements (data not shown). Furthermore, the level (fold stimulation) of natural Sp1-activated transcription was comparable for TBP-hTAF II 250 and TBP-hTAF II 250-hTAF II 135 complexes and fivefold lower than that obtained with natural TFIID (data not shown). Taken together, our data underscore a role of hTAF II 135 in core promoter function rather than a coactivator function both for TR-TRAP and for Sp1, at least as assayed in these partial TFIID complexes. However, it is possible that hTAF II 135 also exhibits a coactivator function, alone or in concert with other TAFs, in natural TFIID. In this regard, it is important to emphasize that natural TFIID promotes relative (fold stimulation) and absolute levels of activation that are higher than those obtained either with TBP alone or with partial TFIID complexes. Natural TFIID achieves this both by inhibiting basal transcription and, in the presence of activator, by reversing this inhibitory effect along with an additional net increase in activation (18) . As discussed earlier, the ability of hTAF II 135 (with TFIIA) to relieve hTAF II 250-mediated inhibition of TBP function in basal transcription, although constrained in natural TFIID relative to partial TFIID complexes, may nonetheless be utilized in TFIID-mediated transcription in response to an activator.
Synergy of TAF II s with TRAP/Mediator complex. The Mediator complex has emerged as a major conduit for communication between gene-specific regulatory factors and the general transcription machinery in both S. cerevisiae (reviewed in references 26 and 32) and human (reviewed in reference 28). Given the observation that individual TAF II s are not universally required for transcription activation in either S. cerevisiae or metazoans, as well as the function of some activators in the absence of TFIID-specific TAF II s in certain cell-free systems from both metazoans and S. cerevisiae, a question of increasing importance is whether the TAF II s may have either redundant or synergistic effects with other prominent coactivators, such as the Mediator.
Here, we have shown that TRAP/Mediator complex synergizes strongly with TAFs in the complete TFIID to potentiate TAF II -mediated activated transcription. Thus, by using intact TFIID, partial TFIID complexes, and TBP, we have dissociated two major functions of TAFs in transcription regulation: intrinsic repressive effects on TBP binding and function that may be core promoter specific and activator-dependent coactivator functions that lead to the reversal of the repressive effects and a large concomitant increase in activation (manifested as synergy with the TRAP/Mediator complex). Because of the above-mentioned properties of TAFs, both the relative (fold stimulation) and absolute levels of activation in the presence of TFIID are usually much higher than those observed in the presence of TBP alone and thus recapitulate more closely the in vivo situation. It is important to note that while activation is observed with TBP, the basal levels are high and the levels of induction (activation/basal transcription ratio) are low; the effect of TAFs is both to lower basal transcription to a more physiological level and, in doing so, to elicit a TRAP requirement for simultaneously reversing the inhibition and effecting high absolute levels of activated transcription plus high levels of induction. Therefore, the presence of all TAFs in the natural TFIID increases the dynamic range of transcription regulation, and TAFs (as a group) can serve as both negative and positive cofactors. TAFs also may be subject to regulation (e.g., setting basal or activated levels) by other interacting cofactors, such as PC4 and the TRAP/Mediator.
